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859-3 Pro B-Natriuretic Peptide (BNP) Measurement for the 
Emergency Diagnosis of Congestive Heart Failure: The 
ProBNP Investigation of Dyspnea in the Emergency 
Department Study (PRIDE)
James L. Januzzi, Jr., Carlos A. Camargo, Saif Anwaruddin, Aaron Baggish, Annabel 
Chen, Daniel Krauser, Roderick Tung, Toby Nagurney, Claudia Chae, Donald M. Lloyd-
Jones, David F. Brown, Patrick M. Sluss, Elizabeth L. Lewandrowski, Kent B. 
Lewandrowski, Massachusetts General Hospital, Boston, MA
Introduction: The role of proB-type natriuretic peptide (proBNP) for the diagnosis of con-
gestive heart failure (CHF) among patients presenting to the Emergency Department
(ED) with dyspnea remains undefined. Accordingly, in the ProBNP Investigation of Dysp-
nea in the Emergency Department (PRIDE) study, we are systematically assessing the
value of proBNP (Elecsys® proBNP Immunoassay, Roche Diagnostics Corporation) for
the urgent evaluation of dyspneic patients with suspected acute CHF.
Methods/Results: Enrollment for the PRIDE study has closed, and clinical follow up is to
complete in October, 2003. The PRIDE study is a single-center, prospective, blinded trial
of 600 patients, age >21 years, presenting with a complaint of dyspnea to an urban ED.
Exclusion criteria include severe renal insufficiency (serum creatinine >2.5 mg/dl), ST
segment depression or elevation on ECG, dyspnea following trauma, and >2 hours fol-
lowing urgent administration of intravenous loop diuretic. Following informed consent,
information regarding demographics, past medical history, current medications, and pre-
sentation of each patient was gathered. A specimen of blood was collected for blinded
proBNP measurement. At the end of standard clinical assessment (history, physical
exam, ECG, chest x-ray), the treating ED physician provided a clinical estimate of the
presence of CHF as the cause of dyspnea. The primary endpoint of the study will be a
comparison of the predictive value of proBNP measurement versus clinical judgment for
the presence of CHF at the time of clinical evaluation in the ED. Other endpoints will
include correlation of proBNP levels with the diagnosis of CHF from presentation to 60
days of follow-up, as well as correlations with hospital length of stay.
Conclusion: The PRIDE study is the first large-scale assessment of proBNP for the eval-
uation of patients with suspected acute CHF in the ED, and will establish a role for this
biomarker in the urgent setting.
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859-4 Nonterminal Pro B-Type Natriuretic Peptide in Patients 
With Chronic Heart Failure: Correlation With B-Type 
Natriuretic Peptide and Left Ventricular Structure and 
Function
Veselin Mitrovic, Inder Anand, Thorsten Dill, Michael Weber, Thomas Notter, Josef 
Schenk, Thomas F. Luescher, Christian W. Hamm, Kerckhoff Heart Center, Bad 
Nauheim, Germany
Background: Plasma levels of B-type natriuretic peptide (BNP) and non terminal pro
BNP (NT-pro BNP) are increased in patients with systolic and diastolic left ventricular
(LV) dysfunction and are important prognostic markers of chronic heart failure. The rela-
tion between NT-pro BNP, BNP, and LV structure and function in patients with chronic
heart failure has not been studied.
Methods: 523 patients (434 male, 89 female, mean age 60.7±11.4 years, LV ejection
fraction 25±10.6%) in NYHA class II-IV, enrolled in the European part of the EARTH
study, and 101 normal control subjects (61.5±7.4 years, ejection fraction 59.0±6.9%),
were studied. LV endsystolic and enddiastolic volumes (ESV, EDV) were measured using
magnetic resonance imaging, ejection fraction, stroke volume, cardiac output, and wall
stress calculated. Plasma NT-pro BNP was measured using a newly developed sandwich
enzyme-linked immunosorbent assay (ELISA) (Elecsys, Roche Diagnostics), and BNP
measurement was performed by use of radio immunoassay (RIA).
Results: NT-pro BNP [median, (25th-75th percentile)] was significantly increased as com-
pared to the controls [942 (492-1977) versus 101 (61-163) pg/ml, p<0.0001]. Area under
receiver operated curve was 0.96. At a cut-off point of 270 pg/ml, the specificity and sen-
sitivity were 92% and 88% respectively. NT-pro BNP correlated significantly with BNP
(r=0.79, p<0.001), LV ejection fraction (r=0.40, p<0.001), EDV (mean±standard devia-
tion=256±94 ml, r=0.40, p<0.0001), ESV (197±91ml, r=0.24, p<0.0001), and wall stress
(63±18, r=0.32, p<0.005), but not with stroke volume or cardiac output. NT-pro BNP lev-
els were significantly higher in patients who died (6 months, 21/523 patients), compared
to those who survived (median NT-pro BNP, 3148 versus 1741 pg/ml, p<0.0001). NT-pro
BNP above the median, and in the 3rd and 4th quartile were accociated with reduced sur-
vival (p<0.001).
Conclusion: NT-pro BNP correlates well with BNP and LV volumes and is a significant
predictor of mortality in patients with chronic heart failure.
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870-1 Chronic Beta3-Adrenergic Receptor Blockade Causes 
Regression of Cardiac Dysfunction in a Rat Model of 
Progressive Heart Failure
Heng-Jie Cheng, Atsushi Morimoto, Hiroshi Hasegawa, Qing-Hua Han, David C. Sane, 
William C. Little, Che-Ping Cheng, Wake Forest University School of Medicine, Winston-
Salem, NC
Background. The negative inotrope and upregulation of β3-adrenergic receptors (AR) in
failing human and animal hearts suggest a direct and contributing role of cardiac β3-AR
activation on heart failure (HF) progression. Therefore, we tested the hypothesis that
chronic β3-AR blockade may limit or prevent the progression of HF.
Methods. Left ventricular (LV) and myocyte functional response and β1- and β3-AR
expression were compared in 3 groups of rats (6 each) for a period of 4 months: 1) Iso-
proterenol (ISO)-treated, 4 months after receiving ISO (340 mg/kg, sq, for 2 days); 2)
ISO/β3-ANT, one month after receiving ISO, L-748,337, a selective β3-AR antagonist (β3-
ANT) (10-7 M/kg/day by implanted osmotic mini pump) was initiated after the onset of HF
and was given for 2 months; and 3) sham controls.
Results. Compared with controls, ISO-treated rats had HF onset at one month after ISO
and progressed to severe CHF at 4 months. Plasma norepinephrine (NE, 1482 vs 247
pg/ml) increased 6 fold. Both stroke volume (SV) and ejection fraction (EF, 34 vs 62%)
decreased more than 45%, and LV end-diastolic pressure (PED, 16.3 vs 6.4 mmHg) dou-
bled, parallel with 49% reductions in cell contraction (dL/dtmax, 95 vs 189 µm/s) and
relaxation (dR/dtmax,75 vs 158 µm/s) and a much less increase in dL/dtmax (32 vs 74%)
in response to superfusion of ISO (10-8 M). These changes were associated with signifi-
cantly decreased β1-AR mRNA (52%, 0.30 vs 0.62), but increased β3-AR mRNA (119%,
1.25 vs 0.57) expression. Treatment with β3-ANT significantly decreased PED and
plasma NE (197 pg/ml). Both SV and EF (59%) increased to more than 75% from ISO-
treated values. The signal ratios of β1-AR mRNA (0.59) and β3-AR mRNA (0.66)
remained close to control levels. ISO-induced increase in dL/dtmax (75%) was also signif-
icantly augmented.
Conclusion. Chronic β3-ANT causes normalization of β1- and β3-AR gene expression,
restores normal responsiveness of myocyte to ß-AR stimulation, and leads to regression
of LV and myocyte dysfunction in a rat model of progressive CHF. Thus, β3-AR blocker
may provide a new therapeutic strategy for the treatment of CHF.
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870-2 In Vivo Evidence of Isolated Impaired Myocardial 
Relaxation in Mice Overexpressing the Transcription 
Factor RTEF-1
Michael A. Mathier, Jennifer J. Rager, Guy A. MacGowan, Alexandre F. Stewart, 
University of Pittsburgh, Pittsburgh, PA
RTEF-1 mediates transcriptional responses to alpha1-adrenergic signaling in cardiac
myocytes. Mice with cardiac-specific overexpression of RTEF-1 develop atrial dilation
and atrial arrhythmias. To assess whether mechanical abnormalities contribute to these
observations, we performed transthoracic echocardiography and pressure-volume con-
ductance catheterization (closed chest via right carotid artery) in RTEF-1 and wild type
(WT) mice (Avertin anesthesia). Conductance catheter data (mean + SD) are summa-
rized in the table. Acute IV volume loading (200 uL NS) revealed no difference between
groups in the slopes of the end-diastolic pressure-volume relation (0.54 vs. 0.68 mmHg/
uL; p=NS), indicating normal passive compliance. This is in keeping with the absence of
myocardial fibrosis seen on pathology. Echocardiography revealed no difference in LV
mass (confirmed by ex vivo heart weights) or dimensions. Doppler interrogation of LV fill-
ing revealed an increase in the E/A ratio in RTEF-1 mice (1.59 + 0.15 vs. 1.26 + 0.23;
p<0.05), mediated by trends toward an increase in the E wave velocity (60 + 18 vs. 55 +
8 cm/s; p=NS) and a decrease in the A wave velocity (38 + 10 vs. 44 + 7 cm/s; p=NS).
Conclusions: Mice overexpressing RTEF-1 exhibit preserved LV systolic function with
impaired relaxation, resulting in elevated filling pressures. While the mechanisms by
which RTEF-1 overexpression impairs LV relaxation are unknown, this may serve as a
useful model of diastolic dysfunction in the absence of LV hypertrophy.
Group HR
(bpm)
LVEDP
(mmHg)
LVEDV
(uL)
EF (%) +dP/dt
(mmHg/sec)
-dP/dt
(mmHg/sec)
tau (ms)
RTEF-1
(n=9)
437 +
53
12.6 + 4.0 16.1 + 4.3 61.3 +
9.1
5883 + 1997 -3745 + 1475 13.3 +
4.8
WT (n=10) 440 +
49
4.9 + 1.1 17.2 + 5.7 62.3 +
8.5
6515 + 1726 -5274 + 1036 7.7 + 1.6
P NS <0.001 NS NS NS <0.01 <0.001
